Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial

Clin Cancer Res (2020) 26 (24): 6437–6444.

https://doi.org/10.1158/1078-0432.CCR-20-1790

Published: 15 December 2020

View article titled, Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial

Includes: Supplementary data

Journal Articles

Abstract PO-067: Tissue banking from patients with SARS-CoV-2 (COVID-19) infection

Emily F. Higgs, Blake A. Flood, Athalia R. Pyzer, Sherin J. Rouhani, Jonathan A. Trujillo, Kyle R. Cron, Alexandra Cabanov, Jessica Fessler, Jeffrey Bloodworth, Kathleen Beavis, Kiang-Teck J Yeo, Randy F. Sweis, Yuanyuan Zha, Thomas F. Gajewski

Clin Cancer Res (2020) 26 (18_Supplement): PO-067.

https://doi.org/10.1158/1557-3265.COVID-19-PO-067

Published: 15 September 2020

View article titled, Abstract PO-067: Tissue banking from patients with SARS-CoV-2 (COVID-19) infection

Journal Articles

Abstract S05-02: COVIDOSE: Low-dose tocilizumab in the treatment of COVID-19 pneumonitis

Clin Cancer Res (2020) 26 (18_Supplement): S05-02.

https://doi.org/10.1158/1557-3265.COVID-19-S05-02

Published: 15 September 2020

View article titled, Abstract S05-02: COVIDOSE: Low-dose tocilizumab in the treatment of COVID-19 pneumonitis

Journal Articles

Abstract S04-02: Treatment with tocilizumab does not inhibit induction of anti-COVID-19 antibodies in patients with severe SARS-CoV-2 infection

Alexandra Cabanov, Blake A. Flood, Jeffrey Bloodworth, Emily F. Higgs, Jessica Fessler, Michael Y.K. Leung, Kyle R. Cron, Jonathan Trujillo, Athalia R. Pyzer, Sherin Rouhani, Garth Strohbehn, Brian Heiss, Mark Ratain, Pankti Reid, Kiang-Teck J. Yeo, Randy F. Sweis, Yuanyuan Zha, Thomas F. Gajewski

Clin Cancer Res (2020) 26 (18_Supplement): S04-02.

https://doi.org/10.1158/1557-3265.COVID-19-S04-02

Published: 15 September 2020

View article titled, Abstract S04-02: Treatment with tocilizumab does not inhibit induction of anti-COVID-19 antibodies in patients with severe SARS-CoV-2 infection

Journal Articles

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

Antoni Ribas, Adil Daud, Anna C. Pavlick, Rene Gonzalez, Karl D. Lewis, Omid Hamid, Thomas F. Gajewski, Igor Puzanov, Matthew Wongchenko, Isabelle Rooney, Jessie J. Hsu, Yibing Yan, Erica Park, Grant A. McArthur

Clin Cancer Res (2020) 26 (1): 46–53.

https://doi.org/10.1158/1078-0432.CCR-18-4180

Published: 03 January 2020

View article titled, Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

Includes: Supplementary data

Journal Articles

Brain Tumor Microenvironment and Host State: Implications for Immunotherapy

William Tomaszewski, Luis Sanchez-Perez, Thomas F. Gajewski, John H. Sampson

Clin Cancer Res (2019) 25 (14): 4202–4210.

https://doi.org/10.1158/1078-0432.CCR-18-1627

Published: 15 July 2019

View article titled, Brain Tumor Microenvironment and Host State: Implications for Immunotherapy

Journal Articles

WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers

Jason J. Luke, Riyue Bao, Randy F. Sweis, Stefani Spranger, Thomas F. Gajewski

Clin Cancer Res (2019) 25 (10): 3074–3083.

https://doi.org/10.1158/1078-0432.CCR-18-1942

Published: 15 May 2019

View article titled, WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers

Includes: Supplementary data

Journal Articles

The Microbiota: A New Variable Impacting Cancer Treatment Outcomes

Jessica L. Fessler, Thomas F. Gajewski

Clin Cancer Res (2017) 23 (13): 3229–3231.

https://doi.org/10.1158/1078-0432.CCR-17-0864

Published: 02 July 2017

View article titled, The Microbiota: A New Variable Impacting Cancer Treatment Outcomes

Journal Articles

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies

Gregory L. Beatty, Peter J. O'Dwyer, Jason Clark, Jack G. Shi, Kevin J. Bowman, Peggy A. Scherle, Robert C. Newton, Richard Schaub, Janet Maleski, Lance Leopold, Thomas F. Gajewski

Clin Cancer Res (2017) 23 (13): 3269–3276.

https://doi.org/10.1158/1078-0432.CCR-16-2272

Published: 02 July 2017

View article titled, First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies

Journal Articles

Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer

Leticia Corrales, Thomas F. Gajewski

Clin Cancer Res (2015) 21 (21): 4774–4779.

https://doi.org/10.1158/1078-0432.CCR-15-1362

Published: 01 November 2015

View article titled, Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer

Journal Articles

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

Clin Cancer Res (2015) 21 (10): 2289–2296.

https://doi.org/10.1158/1078-0432.CCR-14-1630

Published: 14 May 2015

View article titled, Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

Includes: Supplementary data

Journal Articles

Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients

Ezra E.W. Cohen, Kehua Wu, Christine Hartford, Masha Kocherginsky, Kimberly Napoli Eaton, Yuanyuan Zha, Anitha Nallari, Michael L. Maitland, Kammi Fox-Kay, Kristin Moshier, Larry House, Jacqueline Ramirez, Samir D. Undevia, Gini F. Fleming, Thomas F. Gajewski, Mark J. Ratain

Clin Cancer Res (2012) 18 (17): 4785–4793.

https://doi.org/10.1158/1078-0432.CCR-12-0110

Published: 30 August 2012

View article titled, Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients

Includes: Supplementary data

Journal Articles

Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma

Justin Kline, Ian E. Brown, Yuan-Yuan Zha, Christian Blank, John Strickler, Harald Wouters, Long Zhang, Thomas F. Gajewski

Clin Cancer Res (2008) 14 (10): 3156–3167.

https://doi.org/10.1158/1078-0432.CCR-07-4696

Published: 15 May 2008

View article titled, Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma

Includes: Supplementary data

Journal Articles

Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment

Thomas F. Gajewski

Clin Cancer Res (2007) 13 (18): 5256–5261.

https://doi.org/10.1158/1078-0432.CCR-07-0892

Published: 17 September 2007

View article titled, Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment

Journal Articles

Innovations and Challenges in Melanoma: Summary Statement from the First Cambridge Conference

Michael B. Atkins, David E. Elder, Richard Essner, Keith T. Flaherty, Thomas F. Gajewski, Frank G. Haluska, Patrick Hwu, Ulrich Keilholz, John M. Kirkwood, James W. Mier, Merrick I. Ross, Craig L. Slingluff, Vernon K. Sondak, Jeffrey A. Sosman, Martin A. Weinstock, Laura King

Clin Cancer Res (2006) 12 (7): 2291s–2296s.

https://doi.org/10.1158/1078-0432.CCR-05-2560

Published: 11 April 2006

View article titled, Innovations and Challenges in Melanoma: Summary Statement from the First Cambridge Conference

Journal Articles

Identifying and Overcoming Immune Resistance Mechanisms in the Melanoma Tumor Microenvironment

Thomas F. Gajewski

Clin Cancer Res (2006) 12 (7): 2326s–2330s.

https://doi.org/10.1158/1078-0432.CCR-05-2517

Published: 11 April 2006

View article titled, Identifying and Overcoming Immune Resistance Mechanisms in the Melanoma Tumor Microenvironment

Journal Articles

Phase II Trial of the O⁶-Alkylguanine DNA Alkyltransferase Inhibitor O⁶-Benzylguanine and 1,3-Bis(2-Chloroethyl)-1-Nitrosourea in Advanced Melanoma

Thomas F. Gajewski, Jeffrey Sosman, Stanton L. Gerson, Lili Liu, Eileen Dolan, Shang Lin, Everett E. Vokes

Clin Cancer Res (2005) 11 (21): 7861–7865.

https://doi.org/10.1158/1078-0432.CCR-05-0060

Published: 08 November 2005

View article titled, Phase II Trial of the O6-Alkylguanine DNA Alkyltransferase Inhibitor O6-Benzylguanine and 1,3-Bis(2-Chloroethyl)-1-Nitrosourea in Advanced Melanoma

Journal Articles

Phase II Study of the Flk-1 Tyrosine Kinase Inhibitor SU5416 in Advanced Melanoma

Amy C. Peterson, Susan Swiger, Walter M. Stadler, Milica Medved, Greg Karczmar, Thomas F. Gajewski

Clin Cancer Res (2004) 10 (12): 4048–4054.

https://doi.org/10.1158/1078-0432.CCR-03-0766

Published: 24 June 2004

View article titled, Phase II Study of the Flk-1 Tyrosine Kinase Inhibitor SU5416 in Advanced Melanoma

Journal Articles

Immunization of HLA-A2⁺ Melanoma Patients with MAGE-3 or MelanA Peptide-pulsed Autologous Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin 12

Thomas F. Gajewski, Francesca Fallarino, Andrew Ashikari, Matthew Sherman

Clin Cancer Res (2001) 7 (3): 895s–901s.

Published: 01 March 2001

View article titled, Immunization of HLA-A2+ Melanoma Patients with MAGE-3 or MelanA Peptide-pulsed Autologous Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin 12

NARROW

Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial

Abstract PO-067: Tissue banking from patients with SARS-CoV-2 (COVID-19) infection

Abstract S05-02: COVIDOSE: Low-dose tocilizumab in the treatment of COVID-19 pneumonitis

Abstract S04-02: Treatment with tocilizumab does not inhibit induction of anti-COVID-19 antibodies in patients with severe SARS-CoV-2 infection

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

Brain Tumor Microenvironment and Host State: Implications for Immunotherapy

WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers

The Microbiota: A New Variable Impacting Cancer Treatment Outcomes

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies

Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients

Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma

Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment

Innovations and Challenges in Melanoma: Summary Statement from the First Cambridge Conference

Identifying and Overcoming Immune Resistance Mechanisms in the Melanoma Tumor Microenvironment

Phase II Trial of the O⁶-Alkylguanine DNA Alkyltransferase Inhibitor O⁶-Benzylguanine and 1,3-Bis(2-Chloroethyl)-1-Nitrosourea in Advanced Melanoma

Phase II Study of the Flk-1 Tyrosine Kinase Inhibitor SU5416 in Advanced Melanoma

Immunization of HLA-A2⁺ Melanoma Patients with MAGE-3 or MelanA Peptide-pulsed Autologous Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin 12

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only